GAUTING, G - Nov 15, 2016 - Seeing the increasing demand in early-phase clinical trials, Inamed expanded its clinical unit, in order to satisfy the growing request for this type of studies. Therefore today we are pleased to announce that our new Clinical Unit Area has commenced operations.

The new expansion not only contains a lab area and doctors and nurses oces, but also 6 state-of-the-art subject rooms with 12 additional beds, as well as a large multipurpose room for all kinds of pharmacokinetic and pharmacodynamic trials or special safety studies, such as TQT trials. With this new clinical unit area, Inamed now has three separate areas to optimally conduct your clinical studies: the ground oor for ambulatory visits, the rst oor with 12 beds plus 6 intensive monitoring beds (for in-house and FIM studies) and the new area on the second oor with 12 beds and a multitude of additional rooms.

With this new expansion Inamed offers benefits at dierent levels:

• Inamed is able to conduct PK studies with larger cohorts (of up to 2x12 subjects)
• Inamed can run multiple PK/PD studies in parallel which allows additional exibility in terms of dispatching of operations, which is in the well-understood interest of our clients
• Inamed oers a strict separation of dierent in-house studies which meets the highest regulatory demands.

Even though Inamed has built its reputation on respiratory medicine, it is constantly extending its range of activities. For several years now, and even more with this new clinical unit expansion, Inamed is able to oer Phase-I study services in a broader context, for example, all kind of pharmacokinetic and pharmacodynamic trials, proof-of-concept studies using a variety of pharmacodynamic models, or dedicated safety trials, such as TQT trials.

About Inamed
Inamed is an international Contract Research Organization (CRO) providing its clients with the full range of services, required for the planning, conduct and evaluation of clinical trials throughout all phases, for nearly two decades. Founded in 1998, Inamed is located in the periphery of Munich. Complementing our solid experience in conducting clinical trials in various indications, Inamed's team of inhalation and clinical experts provides our sponsors with a unique spectrum of services.

Besides our clinical unit, Inamed also offers clinical trial management services throughout all clinical phases (I-IV) and performs in-vitro investigations in its own labs. Inamed is a leading CRO in continental Europe able to perform scintigraphic lung deposition studies, with radiolabeled compounds, under GMP requirements.

Inamed oers sponsors the opportunity to get their products to market successfully, by generating decisive research data in the highest quality. For more information about Inamed and the scope of services provided by us, please feel free to contact us or take a look at our website: www.inamed-cro.com